Tonic-Clonic Seizures – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tonic-Clonic Seizures Market Outlook

Thelansis’s “Tonic-Clonic Seizures Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Tonic-Clonic Seizures treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Tonic-Clonic Seizures Overview

Tonic-clonic seizure is characterized by a tonic phase and clonic muscle contractions, which was once referred to as a grand mal seizure. Of all the seizure kinds, they are the most feared by patients, families, and onlookers. They are typically linked to either total loss of consciousness or diminished awareness. In the most recent categorization published by the International League Against Epilepsy (ILAE), they fall within the category of seizures with a generalized onset. Motor and non-motor (absence) seizures are subtypes of generalized onset seizures. The majority of generalized tonic-clonic seizures are caused by underlying hereditary epilepsy, which was previously classified as idiopathic epilepsy. Even if a CT scan is negative, further imaging, such as magnetic resonance imaging (MRI), must be performed if there is a high suspicion of localized abnormality. When a patient experiences focal neurological abnormalities that cannot be explained by a structural abnormality or variable mental state or does not return to baseline 30 to 60 minutes following a seizure, emergency electroencephalography is advised. The first line of treatment are benzodiazepine, such as intramuscular midazolam, intravenous lorazepam, intravenous diazepam, intranasal midazolam or rectal diazepam. Second-line therapy should start if seizures last longer than twenty minutes. One of these three antiepileptic medications is intravenous fosphenytoin, levetiracetam, or valproic acid—which can be administered as a single bolus dosage; however, there is no evidence-based recommended second-line therapy.

• In the United States, seizures make up 1% to 2% of all emergency room visits. It is estimated that 11% of Americans may experience a seizure at some point in their lifetime. Males are more likely than females to experience acute symptomatic seizures at a ratio of 1.85 to 1, with a lifetime risk of 5.0% for men and 2.7% for women.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: